Skip to main content
NCBI home page
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures

Tao Shi 1,†, Shuai Zhu 2,†, Hengjuan Guo 3,†, Xiongfei Li 2, Shikang Zhao 2, Yanye Wang 2, Xi Lei 2, Dingzhi Huang 4, Ling Peng 5,*, Ziming Li 6,*, Song Xu 2,*
PMCID: PMC7940546  PMID: 33708622

Abstract

Introduction

Previous studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in patients with early stage resected NSCLC.

Methods

Electronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched until July 23 2020 for studies evaluating the expression of PD-L1 and the prognosis of resected NSCLCs. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS) were pooled and analyzed. Heterogeneity and publication bias analyses were also assessed.

Results

A total of 15 studies involving 3,790 patients were considered in the present meta-analysis. The pooled HR indicated that PD-L1 expression related to a much shorter DFS (HR = 1.56, 95% CI: 1.18–2.05, p < 0.01), as well a significantly worse OS (HR = 1.68, 95% CI: 1.29–2.18, p < 0.01). Furthermore, our analysis indicated that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01–1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38–0.77, p = 0.001), TNM stage (I vs. II–III: OR = 0.45, 95% CI:0.34–0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43, 95% CI:1.14–1.80, p = 0.002) and lymph node metastasis (N+ vs N−: OR = 1.97, 95% CI:1.26–3.08, p = 0.003).

Conclusions

The results of this meta-analysis suggest that PD-L1 expression predicts an unfavorable prognosis in early stage resected NSCLCs. The role of personalized anti-PD-L1/PD-1 immunotherapy in the adjuvant settings of resected NSCLC warrants further investigation.

Keywords: PD-L1, NSCLC, meta-analysis, prognosis, resection

Introduction

Lung cancer is the most commonly diagnosed cancer and a leading cause of cancer-related deaths (1). Surgery is the standard treatment for early stage non-small cell lung cancer (NSCLC); however, postoperative prognosis remains unsatisfactory, with a 5-year survival rate ranging between 71 and 83% (2).Therefore, it is essential to identify new biomarkers for efficient clinical decision making and improve patient outcomes. Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway is one of the most promising immunotherapeutic strategies in boosting the immune system in the fight against cancer (3, 4). Programmed death 1 (PD-1), an important immune checkpoint molecule, is an immune-inhibitory receptor expressed on the surface of activated T cells in response to persistent inflammatory stimuli (5, 6). PD-L1 expressed on the tumor cells binds to the PD-1 receptors on activated T cells, resulting in the inhibition of the cytotoxic T cells. Blockade of the PD-1/PD-L1 pathway with monoclonal antibodies is a promising therapeutic strategy, with prominent clinical benefits of this checkpoint-blockade observed in recent clinical trials (7, 8).

Previously, a study has demonstrated that PD-L1 is a marker of poor prognosis and survival in advanced-stage NSCLC patients (9). A meta-analysis, performed on six studies with 1,157 patients, demonstrated that NSCLC patients with positive PD-L1 expression exhibited a much poorer OS (10). Another meta-analysis by Li et al., which included the largest number of patients (fifty studies with 11,383 patients), also indicated that PD-L1 IHC expression was related to poor overall survival (11). However, the searching deadline for Li’s study was January 2018, and more recent studies focusing on PD-L1 and prognosis in NSCLC were missing. More importantly, all of previous studies, including Li’s study, were performed on the NSCLC patients of both early and advanced stages, and they only took OS into account. Therefore, the impact of PD-L1 expression in the prognosis of patients with early stage NSCLCs following complete resection remains controversial. In the present study, we performed a meta-analysis of all available evidence not only to analyze OS but also assess the correlation between PD-L1 expression and DFS in early stage surgically resected NSCLC patients, which is more accurate and valuable to reflect the influence of PD-L1 expression on the survival of NSCLC.

Methods

This study was reported on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines ( Supplementary Data 1 ).

Relevant studies were retrieved by searching PubMed, Embase, and the Central Registry of Controlled Trials of the Cochrane Library, using the following terms: “Carcinoma, Non-Small Cell Lung” AND “PD-L1 protein, human” AND “Prognosis”. ( Supplementary Data 2 ) The final search period was July 23 2020. Two authors (SX and SZ) performed the search independently. We restricted our research to studies published in English.

Eligible studies were in agreement with the following criteria: (1) the histology type of cancer was NSCLC; (2) valid TNM stage and cancer differentiation, as well as sufficient survival data, such as hazard ratio (HR) with 95% confidence intervals (CI), OS, and DFS were available (3) were published in English; (4) evaluated the association between PD-L1 expression and prognosis or pathological features; (5) involved early stage resectable NSCLC patients; (6) had similar research experimental design and methods; (7) PD-L1 expression was divided into high (positive) and low (negative) categories; and (8) relevant information could be extracted from the full-text study. Exclusion criteria included: (1) duplicate reports, ongoing studies, letters, conference papers, and reviews; (2) studies regarding lung cancer cell lines, animal models, and other types of cancer; (3) studies with insufficient survival data for which HR and CI could not be determined; (4) papers not published in English; (5) methods and experimental design differed from those of the selected studies.

The Newcastle–Ottawa quality assessment scale (NOS) and National Institute for Clinical Excellence (NICE) quality assessment scale was performed to assess methodological quality and risk of bias for cohort studies and case series studies, respectively. The primary outcomes of our study were disease-free survival (DFS) and overall survival (OS). The characteristic details of the publications, including the first author’s name, publication year, tumor type, PD-L1 level, stage, the evaluation method of the PD-L1expression, were extracted by two independent investigators. Any disagreement was discussed between investigators to reach a consensus. Multivariate analysis results were extracted as some included studies performed univariate analysis. We used the data directly from the included studies, providing precise HR (95% CI). In the case of studies only providing Kaplan–Meier survival curves, the Engauge Digitizer version 2.11 software was used to extract relevant numerical values from survival curves and calculate the HR (95% CI) (12, 13).

The STATA 15.0 (Stata Corporation, College Station, USA) software and R package 4.0.2 were used for data synthesis and analysis.

The random-effects model was employed in case of potential heterogeneity and to avoid underestimation of standard errors of pooled estimates in this meta-analysis. HRs for DFS and OS with 95% CIs according to the expression status of PD-L1 were pooled. The pooled odds ratios (ORs) were used to investigate the correlation between PD-L1 expression and clinicopathological features.

The heterogeneity test was performed using the Cochrane’s Q test (Chi-squared test; Chi2) and I2 metric (14). A chi-squared P value <0.1 or an I2 statistic >50% was defined as statistically significant heterogeneity (15). Moreover, the potential publication bias was assessed through Begg’s funnel plots (16). P <0.05 was considered as statistically significant based on the two-sided test. Subgroup analysis was conducted according to gender, histology, TNM stage, smoking status, and lymph node metastasis. An HR >1 reflected longer OS or DFS for PD-L1 negative patients.

Sensitivity analyses (17) were conducted to investigate the influence of a specific study on the pooled risk estimate by removing one study in each turn ( Figures 2D , 3D , Supplementary Data 3 ).

Figure 2.

Figure 2

Open in a new tab

Pooled analysis of DFS according to PD-L1 expression. (A) Forest plot of HR for the association between PD-L1 expression and DFS with early stage resected non-small cell lung cancer; (B) Funnel graph of potential publication bias of HR for DFS in the eligible studies by Egger’s test; (C) Funnel graph of potential publication bias of HR for DFS in the eligible studies by Begg’s test. (D) Sensitivity analysis for DFS via elimination of each study in turn.

Figure 3.

Figure 3

Open in a new tab

Pooled analysis of OS according to PD-L1 expression. (A) Forrest plot of HR for the association between PD-L1 expression and OS with early stage resected non-small cell lung cancer; (B) Funnel graph of potential publication bias of HR for OS in the eligible studies by Egger’s test; (C) Funnel graph of potential publication bias of HR for OS in the eligible studies by Begg’s test. (D) Sensitivity analysis for OS via elimination of each study in turn.

Results

We identified 1,719 potentially relevant records through our search. A total of 1,558 studies were excluded after reviewing the title and abstract as their research contents failed to meet our inclusion criteria. Subsequently, the full texts of 92 articles were carefully screened, and a total of 15 studies (18–32) were found eligible for the final analysis. Figure 1 summarizes the flow chart depicting the process followed for study selection. No article was excluded by methodological quality and risk of bias and sensitivity analysis for significant heterogeneity ( Figures 2D , 3D ).

Figure 1.

Figure 1

Open in a new tab

Flow chart of selection process to identify studies eligible for pooling.

In all articles, resectability was a necessary intervention. All 15 studies were retrospective and published between 2016 and 2020. Fourteen of 15 studies recorded OS data, while only eight out of 15 studies presented only DFS information. Overall, 15 studies comprising of 3,790 patients were included in the pooled analysis and, all selected studies used immunohistochemistry or H-score assays to evaluate PD-L1 expression in tumor cells and/or tumor-infiltrating lymphocytes (TILs). Table 1 summarized the characteristics of all involved studies, including peri-operative therapy and PD-L1 detection information.

Table 1.

Summary characteristics of included studies.

Author Years Region NOS(star) /NICE Cancer type Perioperative adjuvant therapy Stage Method PD-L1 expression Number Antibody Outcome
Cut-off values Negative Positive Company Source Type Clone
Kinoshita et al. (18) 2020 Japan 7 AD NP I IHC 1% 155 48 203 Spring Biosclence, USA Mouse MAB SP142 OS PFS
Gachechiladze et al. (19) 2020 Europe 8 NSCLC 12% neoadjuvant CT or CRT; 31% adjuvant CT; 18% adjuvant RT I-III IHC NA 755 109 864 NA Rabbit PAB SP263 OS
Li et al. (20) 2020 China 6 NSCLC NP I-III IHC 5% 56 31 87 NA Rabbit DAB 66248-1-Ig OS PFS
Meng et al. (21) 2019 China 7 NSCLC 29% adjuvant CT; 22% adjuvant CRT I-III IHC 10% NA NA 197 Abcam, USA Rabbit NA 28-8 OS
Kim et al. (22) 2019 Korea 7 AD NP I-III IHC 5% 241 60 301 Spring Bioscience, USA Rabbit DAB SP142 OS
Teramoto et al. (23) 2019 Japan 6 NSCLC 25% adjuvant CT I-III IHC 50% 104 21 125 Cell Signaling Technology, USA Mouse DAB E1L3N PFS
Cao et al. (24) 2017 China 7 NSCLC 61% adjuvant therapy* I-III IHC 50% 283 81 364 Cell Signaling Technology, USA Mouse DAB EIL3N OS PFS
Song et al. (25) 2016 China 7 AD 70% adjuvant therapy* I-III IHC 5% 199 186 385 Proteintech Group Inc.,USA Rabbit NA 66248-1-Ig OS PFS
Okita et al. (26) 2017 Japan 6 NSCLC NP I-III H-socre 100 78 13 91 Spring Biosclence, USA Mouse MAB SP142 OS PFS
Sepesi et al. (27) 2017 America 7 NSCLC 21% adjuvant therapy* I IHC 4.69% 87 26 113 Cell Signaling Technology,USA NA NA E1L3N OS
Imanishi et al. (28) 2018 Japan 6 NSCLC 35% adjuvant therapy* I-III IHC 15% 16 10 26 Cell Signaling Technology,Japan Rabbit NA E1L3N OS
Zaric et al. (29) 2018 Austria 7 AD 46% adjuvant CT;7% adjuvant RT I-III IHC 1% 102 59 161 Cell Signaling Rabbit NA E1L3N OS PFS
Takamori et al. (30) 2019 Japan 8 AD NP I-III IHC 1% 287 146 433 Spring Bioscience,USA NA NA SP142 OS PFS
Matsubara et al. (31) 2019 Japan 7 SCC NP I-III IHC 5% 134 77 211 Spring Bioscience, USA Rabbit DAB SP142 OS
Igawa et al. (32) 2017 Japan 7 NSCLC 15% adjuvant therapy* I-III H-socre 100 109 120 229 Ventana Medical Systems, USA Rabbit PAB SP263 OS
Open in a new tab

NSCLC, non-small cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; IHC, immunohistochemistry; OS, overall survival; DFS, disease-free survival; NA, not available; NP, not provided; CT, chemotherapy; CRT, chemo/radiotherapy; RT, radiotherapy.

*The exact means of therapy (CT, RT or CRT) is not clearly mentioned.

As shown in Figure 2A , the overall pooled HR indicated that the high PD-L1 expression was related to a significantly shorter DFS (HR = 1.56, 95% CI: 1.18–2.05, p < 0.01). Further analysis demonstrated heterogeneity among the eight studies (I² = 64%, p<< 0.01), and we hence performed Egger’s and Begg’s tests. According to Egger’s test (p = 0.671, Figure 2B ) and Begg’s test (p = 0.620, Figure 2C ), no publication bias influenced the HRs for DFS. Additionally, this confirmed that a negative correlation existed between PD-L1 expression and DFS in the case of resectable NSCLC patients.

In NSCLC patients, the positive expression of PD-L1 on tumor tissues was associated with significantly poorer OS when compared to those indicating negative PD-L1 expression (HR = 1.68, 95% CI: 1.29–2.18, p < 0.01, Figure 3A ). Furthermore, heterogeneity was observed among the 15 studies (I² = 73%, P < 0.01). However, Egger’s (p = 0.595, Figure 3B ) and Begg’s tests (p = 0.411, Figure 3C ) demonstrated no publication bias influencing the HRs for OS, confirming the negative correlation of PD-L1 expression and OS for resectable NSCLC patients.

The correlation of PD-L1 expression and clinical characteristics was further analyzed, including gender, histology, tumor stage, smoking status, and lymph node metastasis. We observed that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01–1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38–0.77, p = 0.001), TNM stage (I vs. II–III: OR = 0.45, 95% CI:0.34–0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43,95% CI:1.14–1.80, p = 0.002) and lymph node metastasis (N+ vs N−:OR = 1.97, 95%CI:1.26–3.08, p = 0.003) ( Table 2 ).

Table 2.

The relationship between PD-L1 expression and clinicopathologic features.

Clinicopathological characteristics No. of studies Heterogeneity OR 95%CI P-value
P-value I² (%)
Gender (male vs. female) 8 0.023 16.2 1.27 1.01-1.59 0.038
Histology (ADC vs. SCC) 5 0.044 8.12 0.54 0.38-0.77 0.001
TNM stage (I vs. II-III) 5 0.000 40.2 0.45 0.34-0.60 0.000
Smoking status (yes vs. no) 8 0.008 18.9 1.43 1.14-1.80 0.002
Lymph node metastasis (N+ vs. N0) 3 0.425 1.71 1.97 1.26-3.08 0.003
Open in a new tab

AD, adenocarcinoma; SCC, squamous cell carcinoma; OR, odds ratio; 95%CI, 95%confidence intervals.

In addition, we also investigated the different cutoff values of PD-L1 expression on the survival. We found that PD-L1 expression at 5% cutoff value was not correlated to DFS (HR = 1.39, 95% CI: 0.89–2.17, p = 0.142) ( Supplementary Data 4 ), but indicated a significantly worse OS (HR = 1.93, 95% CI: 1.57–2.36, p = 0.000) ( Supplementary Data 5 ). However, PD-L1 expression at 1% cutoff value was correlated with a poor DFS (HR = 1.76, 95% CI: 1.03–3.02, p = 0.040) ( Supplementary Data 6 ) but not for OS (HR = 2.19, 95% CI: 0.66–7.22, p = 0.199) ( Supplementary Data 7 ). We propose that the discrepancy for these findings may be attributed to limited data and non-uniform PD-L1 detection platforms.

Discussion

Immune checkpoint inhibitors targeting PD-1/PD-L1 have improved survival in patients with advanced NSCLC in second- and first-line settings (33–37). The PACIFIC trial reported a DFS benefit in patients with locally advanced, unresectable stage III NSCLC who received durvalumab consolidation therapy (38). Owing to the success of immune checkpoint inhibitors in advanced NSCLC, these agents are currently under investigation in the neo- or adjuvant setting for resected NSCLC patients (39–42) Therefore, it is important to understand the impact of PD-1/PD-L1 expression on the prognosis of early stage, resected NSCLC patients. Several studies have demonstrated that PD-L1 is a biomarker indicating poor prognosis and survival in advanced-stage NSCLC patients. However, as reported by previous studies, the expression of PD-L1 on the prognosis of early stage resected NSCLC remains controversial. A comprehensive analysis is required to integrate all available data and provide further insight on this issue.

By summarizing the data available from included studies, our results confirmed that the PD-L1 expression indicates an unfavorable prognosis in early stage resected NSCLC as well. Our conclusion that PD-L1 positive or high expression indicated a significantly inferior OS in early stage resected NSCLC, is consistent with the previous analysis for all stages or advanced stage NSCLC patients (9–11). Additionally, we demonstrate that DFS, which was not explored by the previous studies, is also negatively correlated with PD-L1 expression in early stage resected NSCLC. Lastly, based on subgroup analysis, we observed that the PD-L1 expression was associated with gender, histology, tumor stage, smoking status, and lymph node metastasis.

Our analysis provided evidence to support that the PD-L1 expression may have prognostic value in predicting survival of patients with resected NSCLC. However, there were several limitations to our study. Firstly, this was based on a retrospective analysis. A prospective analysis is required to further clarify these issues. Secondly, 12 out of 15 included studies were performed in Asian population. Although it was not our intention to ignore the data from non-Asian population, the lack of data from non-Asian population is still a limitation for our meta-analysis. Therefore, future investigation should focus more on the PD-L1 expression in early stage non-Asian NSCLC patients. Thirdly, the different adjuvant treatment strategies post-surgery and follow-up also influence the survival of patients with NSCLC undergoing resection, which could have influenced the analysis. Moreover, the cutoff value of the defined PD-L1 expression was rather different among the included studies. We have to categorize high (positive) and low (negative) PD-L1 expression and study the correlation between PD-L1 expression and post-operative survival. Finally, the platform and antibody of PD-L1 detection was not uniform either in the included studies. We have mentioned this issue in Table 1 .

Conclusions

In conclusion, our meta-analysis suggests that PD-L1 expression indicates an unfavorable prognosis in early stage resected NSCLC patients. In the adjuvant settings resected NSCLC, the role of individualized anti-PD-L1/PD-1 immunotherapy merits further investigated.

Data Availability Statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding authors.

Author Contributions

TS, SZ, and HG retrieved and analyzed all of the data in the study. XFL, YW, XL, and SKZ revised the manuscript for important intellectual contents. LP and DH reviewed and edited the manuscript. SX, ZL, and LP designed, checked, and supervised all study processes. All authors contributed to the article and approved the submitted version.

Funding

The present study was funded by the National Natural Science Foundation of China (No. 81772464), Natural Science Foundation of Zhejiang Province, China (No. LY19H160041), Shanghai Science and Technology Commission Guidance Projects (No. 18411968200), Medical-Engineering Joint Funds from Shanghai Jiao Tong University (No. YG2017MS81) and Shanghai Chest Hospital Project of Collaborative Innovation (No. YJXT20190209).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.567978/full#supplementary-material

Supplementary Data Sheet 1

The PRISMA checklist of the manuscript.

Click here for additional data file. (66KB, doc)
Supplementary Data Sheet 2

The search strategy of the manuscript.

Click here for additional data file. (21.1KB, docx)
Supplementary Data Sheet 3

The data of sensitivity analyses.

Click here for additional data file. (56.8KB, docx)
Supplementary Data Sheet 4

Forest plot of HR for the association between PD-L1 expression and DFS with early stage resected non-small cell lung cancer. (PD-L1 expression at 5% cutoff value).

Click here for additional data file. (1.5MB, jpeg)
Supplementary Data Sheet 5

Forest plot of HR for the association between PD-L1 expression and OS with early stage resected non-small cell lung cancer. (PD-L1 expression at 5% cutoff value).

Click here for additional data file. (1.8MB, jpeg)
Supplementary Data Sheet 6

Forest plot of HR for the association between PD-L1 expression and DFS with early stage resected non-small cell lung cancer. (PD-L1 expression at 1% cutoff value).

Click here for additional data file. (1.6MB, jpeg)
Supplementary Data Sheet 7

Forest plot of HR for the association between PD-L1 expression and OS with early stage resected non-small cell lung cancer. (PD-L1 expression at 1% cutoff value).

Click here for additional data file. (1.6MB, jpeg)

References

  • 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2018) 68(6):394–424.   10.3322/caac.21492 [DOI] [PubMed] [Google Scholar]
  • 2. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thoracic Oncol (2016) 11(1):39–51.   10.1016/j.jtho.2015.09.009 [DOI] [PubMed] [Google Scholar]
  • 3. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 24(2):207–12.   10.1016/j.coi.2011.12.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Practice (2015) 21(6):451–67.   10.1177/1078155214538087 [DOI] [PubMed] [Google Scholar]
  • 5. Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Modern Pathol (2017) 30(2):278–85.   10.1038/modpathol.2016.185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Trans Med (2016) 8(328):328rv4.   10.1126/scitranslmed.aad7118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Zheng P, Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers Cancer (2015) 7(Suppl 2):15–8.   10.4137/bic.s29325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J. Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Front Pharmacol (2018) 9:536.   10.3389/fphar.2018.00536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer (Amsterdam Netherlands) (2017) 104:1–6.   10.1016/j.lungcan.2016.11.023 [DOI] [PubMed] [Google Scholar]
  • 10. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol (2015) 41(4):450–6.   10.1016/j.ejso.2015.01.020 [DOI] [PubMed] [Google Scholar]
  • 11. Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Transl Lung Cancer Res (2019) 8(4):429–49.   10.21037/tlcr.2019.08.04 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 17(24):2815–34.   [DOI] [PubMed] [Google Scholar]
  • 13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 8:16.   10.1186/1745-6215-8-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess (Winchester Engl) (2005) 9(12):1–113.   10.3310/hta9120 [DOI] [PubMed] [Google Scholar]
  • 15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed) (2003) 327(7414):557–60.   10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 50(4):1088–101. [PubMed] [Google Scholar]
  • 17. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol (2008) 37(5):1148–57.   10.1093/ije/dyn065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Kinoshita F, Takada K, Yamada Y, Oku Y, Kosai K, Ono Y, et al. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. Ann Surg Oncol (2020) 27(6):2102–9.   10.1245/s10434-019-08029-9 [DOI] [PubMed] [Google Scholar]
  • 19. Gachechiladze M, Škarda J, Skanderová D, Überall I, Kolek V, Smičkova P, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer (Amsterdam Netherlands) (2020) 147:30–8.   10.1016/j.lungcan.2020.06.025 [DOI] [PubMed] [Google Scholar]
  • 20. Li X, Xu Z, Cui G, Yu L, Zhang X. BTLA expression in stage I–III non–small-cell lung cancer and its correlation with PD-1/PD-L1 and clinical outcomes. OncoTargets Ther (2020) 13:215–24.   10.2147/OTT.S232234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Meng X, Gao Y, Yang L, Jing H, Teng F, Huang Z, et al. Immune Microenvironment Differences Between Squamous and Non-squamous Non–small-cell Lung Cancer and Their Influence on the Prognosis. Clin Lung Cancer (2019) 20(1):48–58.   10.1016/j.cllc.2018.09.012 [DOI] [PubMed] [Google Scholar]
  • 22. Kim M, Chung YS, Kim KA, Shim HS. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung. Lung Cancer (Amsterdam Netherlands) (2019) 137:129–35.   10.1016/j.lungcan.2019.09.026 [DOI] [PubMed] [Google Scholar]
  • 23. Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, et al. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Lung Cancer (Amsterdam Netherlands) (2019) 137:56–63.   10.1016/j.lungcan.2019.09.013 [DOI] [PubMed] [Google Scholar]
  • 24. Cao L, Wang X, Li S, Zhi Q, Wang Y, Wang L, et al. PD-L1 is a prognostic biomarker in resected NSCLC patients with moderate/high smoking history and elevated serum SCCA level. J Cancer (2017) 8(16):3251–60.   10.7150/jca.21118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Song Z, Yu X, Cheng G, Zhang Y. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med (2016) 14(1):188.   10.1186/s12967-016-0943-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother: CII (2017) 66(7):865–76.   10.1007/s00262-017-1986-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, et al. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thoracic Cardiovasc Surg (2017) 29(3):408–15.   10.1053/j.semtcvs.2017.05.008 [DOI] [PubMed] [Google Scholar]
  • 28. Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, et al. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. J Surg Oncol (2018) 117(7):1563–9.   10.1002/jso.25041 [DOI] [PubMed] [Google Scholar]
  • 29. Zaric B, Brcic L, Buder A, Brandstetter A, Buresch JO, Traint S, et al. PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. Clin Lung Cancer (2018) 19(6):e957–e63.   10.1016/j.cllc.2018.08.014 [DOI] [PubMed] [Google Scholar]
  • 30. Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, et al. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Ann Surg Oncol (2019) 26(6):1916–24.   10.1245/s10434-019-07231-z [DOI] [PubMed] [Google Scholar]
  • 31. Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, et al. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Ann Surg Oncol (2019) 26(6):1925–33.   10.1245/s10434-019-07257-3 [DOI] [PubMed] [Google Scholar]
  • 32. Igawa S, Sato Y, Ryuge S, Ichinoe M, Katono K, Hiyoshi Y, et al. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology (2017) 92(5):283–90.   10.1159/000458412 [DOI] [PubMed] [Google Scholar]
  • 33. Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(2):123–35. 10.1056/NEJMoa1504627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(17):1627–39.   10.1056/NEJMoa1507643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London Engl) (2016) 387(10027):1540–50. 10.1016/S0140-6736(15)01281-7 [DOI] [PubMed] [Google Scholar]
  • 36. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (2017) 389(10066):255–65.   10.1016/s0140-6736(16)32517-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med (2016) 375(19):1823–33.   10.1056/NEJMoa1606774 [DOI] [PubMed] [Google Scholar]
  • 38. Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med (2017) 377(20):1919–29. 10.1056/NEJMoa1709937 [DOI] [PubMed] [Google Scholar]
  • 39.Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small CellLung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS).
  • 40.Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC.
  • 41.Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010].
  • 42.Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer(ANVIL).

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Data Sheet 1

The PRISMA checklist of the manuscript.

Click here for additional data file. (66KB, doc)
Supplementary Data Sheet 2

The search strategy of the manuscript.

Click here for additional data file. (21.1KB, docx)
Supplementary Data Sheet 3

The data of sensitivity analyses.

Click here for additional data file. (56.8KB, docx)
Supplementary Data Sheet 4

Forest plot of HR for the association between PD-L1 expression and DFS with early stage resected non-small cell lung cancer. (PD-L1 expression at 5% cutoff value).

Click here for additional data file. (1.5MB, jpeg)
Supplementary Data Sheet 5

Forest plot of HR for the association between PD-L1 expression and OS with early stage resected non-small cell lung cancer. (PD-L1 expression at 5% cutoff value).

Click here for additional data file. (1.8MB, jpeg)
Supplementary Data Sheet 6

Forest plot of HR for the association between PD-L1 expression and DFS with early stage resected non-small cell lung cancer. (PD-L1 expression at 1% cutoff value).

Click here for additional data file. (1.6MB, jpeg)
Supplementary Data Sheet 7

Forest plot of HR for the association between PD-L1 expression and OS with early stage resected non-small cell lung cancer. (PD-L1 expression at 1% cutoff value).

Click here for additional data file. (1.6MB, jpeg)

Data Availability Statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES